FDA grants Priority Review to Gilotrif for uncommon EGFR mutations in advanced NSCLC
Boehringer Ingelheim announced that the supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) has been accepted for filing and granted Priority Review by the U.S. Food and…
Read More...
Read More...